Kidney transplant drug showdown: which prevents rejection better?
NCT ID NCT02377193
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tested two different medicines (Simulect and ATG) given right after a kidney transplant to prevent the body from rejecting the new organ. It included 60 patients who were at higher risk of rejection due to prior immune sensitivity. The goal was to see which drug works better at preventing treatment failure, such as rejection or graft loss, within the first 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UHToulouse
Toulouse, France, 31059, France
Conditions
Explore the condition pages connected to this study.